Tag Archives: Zytiga

New Prostate Cancer Agent Improves Survival by Nearly 5 Months!

Posted on March 5, 2012 by wngai

Excellent news for prostate cancer patients whose cancer has progressed after hormonal treatment and chemotherapy!   An experimental oral agent, MDV3100 (Medivation) was found to improve survival in metastatic castration-resistant prostate cancer by 4.8 months The new agent, called MDV3100, is … Continue reading →

Posted in Cancer, Prostate cancer | Tagged , , , , , , , , , , , , , , , , , | Comments Off on New Prostate Cancer Agent Improves Survival by Nearly 5 Months!

A New Agent That Might Change the Lives of Many Cancer Patients

Posted on October 16, 2011 by wngai

This is not only good news for all prostate cancer patients, but is also good news for all cancer patients. The investigational radiopharmaceutical radium-223 chloride (Alpharadin) has recently been shown to improve survival in patients with advanced prostate cancer and … Continue reading →

Posted in Anal Cancer, Bladder Cancer, Breast cancer, Cancer, Colorectal cancer, Endometrial Cancer, Esophageal Cancer, Gallbladder cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma, Nasopharyngeal Cancer, Non Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate cancer, Renal Cancer, Small Cell Lung Cancer, Thyroid Cancer | Tagged , , , , , , , , , , , , , , , , , | Comments Off on A New Agent That Might Change the Lives of Many Cancer Patients

New Prostate Cancer Drug Approved by FDA

Posted on May 30, 2011 by wngai

Good news for patients with metastatic prostate cancer.  The FDA (US Food and Drug Administration) has approved Johnson & Johnson’s Zytiga (abiraterone) in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy.  Abiraterone … Continue reading →

Posted in Cancer, Prostate cancer | Tagged , , , , , , , , , | 1 Comment